This MedLibrary.org supplementary page on Raphael Mechoulam is provided directly from the open source Wikipedia as a service to our readers. Please see the note below on authorship of this content, as well as the Wikipedia usage guidelines. To search for other content from our encyclopedia supplement, please use the form below:
Related Sponsors
| Raphael Mechoulam | |
 Raphael Mechoulam
|
|
| Born | 1930 Sofia, Bulgaria |
|---|---|
| Residence | Jerusalem |
| Citizenship | Israel |
| Fields | Medicinal Chemistry, Natural Products |
| Institutions | Weizmann Institute of Science, Rockefeller University, Hebrew University of Jerusalem |
| Doctoral advisor | Prof. Franz Sondheimer |
| Known for | Total synthesis of tetrahydrocannabinol, major contributions to the chemistry of cannabinoids and discovery of endocannabinoids |
Raphael Mechoulam (Hebrew: רפאל משולם) is an Israeli professor for Medicinal Chemistry and Natural Products at the Hebrew University of Jerusalem in Israel.
Birth and education
Raphael Mechoulam was born in Sofia, Bulgaria on November 5, 1930. His father was a physician and head of a local hospital, while his mother "who had studied in Berlin, enjoyed the life of a well-to-do Jewish family". He attended an "American Grade School" until his parents were forced to leave their hometown because of anti-semitic laws. After the communist takeover of Bulgaria in 1944 he studied chemical engineering which he "disliked". In 1949 his family immigrated to Israel where later studied chemistry. He gained his first research experience in the Israeli Army working on insecticides. He finished his PhD thesis about the chemistry of steroids under the supervision of Prof. Franz Sondheimer in 1950s. After a postdoctoral stay at the Rockefeller Institute with Prof. S. William Pelletier he became a junior member at the Weizmann Institute of Science.
Academic career
Raphael Mechoulam, while being a junior member at the Weizmann Institute of Science, succeeded in the isolation, structure elucidation and total synthesis of Δ9-tetrahydrocannabinol, the main active principle of marihuana. He later became a full professor for medicinal chemistry at the Hebrew University of Jerusalem where he established the "Department of Natural Products". His major scientific interest is the chemistry and pharmacology of cannabinoids. He and his research group succeeded in the total synthesis of the major plant cannabinoids Δ9-tetrahydrocannabinol, cannabidiol, cannabigerol and various others. Another research project initiated by him led to the isolation of the first described endocannabinoid anandamide which was isolated and characterized by two of his postdoctoral researchers, Lumír Hanuš and William Devane. Another endogenous cannabinoid, 2-AG, was soon discovered by Shimon Ben-Shabat, one of his PhD students. He published more than 350 scientific articles and was awarded several prizes, including the Heinrich Wieland prize, Ulf von Euler Lecture in Physiology and the Israel prize among others. The International Cannabinoid Research Society established the "Raphael Mechoulam Annual Award in Cannabinoid Research" in 1999. He is an elected member of the Israeli Academy of Sciences.
References
Mechoulam R (June 2007). "Conversation with Raphael Mechoulam". Addiction (Abingdon, England) 102 (6): 887–93. doi:. PMID 17523982.
"School of Pharmacy - Prof. Mechoulam".
Wikipedia content modification information:
- This page was last modified on 20 November 2008, at 16:52.
Wikipedia Authorship and Review
Wikipedia content provided here is not reviewed directly by MedLibrary.org. Wikipedia content is authored by an open community of volunteers and is not produced by or in any way affiliated with MedLibrary.org.
Wikipedia Usage Guidelines
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article on "Raphael Mechoulam".
The URL for this specific entry is:
All Wikipedia text is available under the terms of the GNU Free Documentation License. (See Copyrights for details). Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc.